65 research outputs found

    Constraining Of The MinerőĹa Medium Energy Neutrino Flux Using Neutrino-Electron Scattering

    Get PDF
    Long baseline neutrino oscillation experiments rely on the flux from accelerator-based neutrino beams. As experimental neutrino physics moves to the next generation of experiments a precise characterization of the neutrino flux on a given experiment becomes crucial to the goals of the experiments: to precisely determine the neutrino oscillation parameters.This work takes advantage of neutrino-electron scattering processes for their precisely predicted cross section. The observed number of scattering events can be used as a benchmark to constrain the neutrino flux. A measurement was made of the energy spectrum of neutrino-electron elastic scattering (őĹe-‚ÜíőĹe-), using data from the antineutrino-enhanced run period of the NuMI beam line with an energy peak at 6 GeV. These new data were combined with previous measurements of neutrino-electron elastic scattering and inverse muon decay (őĹ_őľ e- ‚Üí őľ-őĹ_e). A Bayesian probability technique was applied to constrain the multi-simulation prediction of the neutrino flux. A constraint was set on the normalization and uncertainty of the NuMI neutrino flux at the MINERvA detector. The fractional uncertainty on the integrated neutrino flux was reduced from 7.6\% to 3.3\% for the muon neutrino beam and from 7.8\% to 4.7\% for the muon antineutrino beam. The reduced flux uncertainty will improve the precision of \minerva cross sections measurements. Additionally, the technique demonstrated in this work can be applied to other accelerator-based neutrino experiments as tool to characterize the neutrino flux

    INGESTA DE ARS√ČNICO DE AGUA POTABLE EN LA POBLACI√ďN DE HERMOSILLO SONORA

    Get PDF
    Este estudio fue dise√Īado para evaluar la distribuci√≥n de ars√©nico (As) en el agua potable de Hermosillo, Sonora, M√©xico y analizar los perfiles de metabolitos de As urinario en dos comunidades de la poblaci√≥n, con el fin de proporcionar datos de referencia para estudios de asociaci√≥n relacionados a la salud. Hogares de dos comunidades fueron seleccionadas por sus diferentes concentraciones de As en el suministro de agua potable. Se obtuvieron caracter√≠sticas socio-demogr√°ficas y de estilo de vida de la poblaci√≥n y muestras de agua de todas las fuentes de los hogares. Las concentraciones totales de As en muestras de orina y del agua se determinaron utilizando ICP-MS. Los an√°lisis de especiaci√≥n de las muestras de orina se analizaron utilizando HPLC. La concentraci√≥n media de As total en el agua potable fue de 8,8 g/L y 26,4 g/L, para las comunidades estudiadas. La concentraci√≥n media de As total urinario fue de 74,2 g/L y 47,2 g/L y la del As inorg√°nico urinario fue de 37,7 g/L y 26,4 g/L, respectivamente para los dos grupos de poblaci√≥n. La suma de las especies de As urinarias fue significativamente diferente entre las dos comunidades (

    ACTIVIDADES BIOL√ďGICAS DEL EXTRACTO METAN√ďLICO DE Rhodosorus marinus

    Get PDF
    Las microalgas marinas pueden ser una fuente de moléculas bioactivas; existen numerosos reportes de actividad antioxidante, antibacteriana y antiproliferativa de extractos obtenidos a partir de macroalgas. El objetivo del presente trabajo fue evaluar la actividad citotóxica, antioxidante y antimutagénica del extracto metanólico de la microalga roja Rhodosorus marinus. El extracto fue obtenido a partir de biomasa liofilizada mediante lisis ácida y sonicación. Se evaluó la actividad citotóxica frente a 7 líneas celulares humanas con el ensayo MTT, la actividad antioxidante por ABTS y DPPH y la actividad antimutagénica con las cepas TA98 y TA100 del ensayo de Ames. Se encontró actividad citotóxica frente a 5 de las 7 líneas evaluadas. Los porcentajes de inhibición para la actividad antioxidante fueron de 25.60 + 4.03% (DPPH) y 5.59 + 0.63% (ABTS). Para el ensayo de Ames, frente a ambasm cepas probadas se alcanzaron porcentajes de inhibición de colonias revertantes de aproximadamente el 75% en la concentración más alta evaluada, lo cual indica una fuerte actividad antimutagénica. Los resultados mostraron actividad biológica en las diferentes pruebas realizadas, por lo que se infiere que el extracto metanólico contiene moléculas bioactivas de importancia en la salud y para diferentes usos biotecnológicos

    LAS ALGAS Y OTROS ORGANISMOS MARINOS COMO FUENTE DE MOL√ČCULAS BIOACTIVAS

    Get PDF
    En a√Īos recientes, el incremento en la resistencia a los f√°rmacos antiproliferativos utilizados en el tratamiento del c√°ncer (Ling et al., 2010), as√≠ como en la resistencia bacteriana (Chang et al., 2003; Whichard et al., 2007) se han convertido en problemas de mucho inter√©s para la salud p√ļblica. En la actualidad, no existe una terapia 100% efectiva contra el c√°ncer diseminado y aunque las terapias pueden ser altamente espec√≠ficas, se ha observado que la resistencia es intr√≠nseca al c√°ncer y a medida que las terapias son m√°s efectivas, la resistencia adquirida tambi√©n lo es (Gottesman, 2002). Por otro lado, Las infecciones causadas por bacterias resistentes no responden al tratamiento ordinario y como consecuencia se eleva el riesgo de mortalidad. Solo por citar un ejemplo, cada a√Īo se registran incidencias globales de 440000 casos de tuberculosis multirresistente con √≠ndices de mortalidad que superan las 150000 defunciones. La tuberculosis ultrarresistente se ha notificado en 64 pa√≠ses (OMS, 2012). El r√°pido aumento en la resistencia a los f√°rmacos antiproliferativos y antibacterianos induce a tomar varias medidas de control, entre las cuales se puede mencionar la necesidad de buscar nuevas fuentes de mol√©culas bioactivas

    Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission

    Get PDF
    Introduction & objectives: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal liver tests on admission of hospitalized patients with COVID-19. Materials & methods: We performed a prospective cohort study including 1611 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through July 31, 2020 in 38 different Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters, including liver function tests, on admission and during hospitalization. All patients were followed until discharge or death. We fit multivariable logistic regression models, further post-estimation effect through margins and inverse probability weighting. Results: Overall, 57.8% of the patients were male with a mean age of 52.3 years, 8.5% had chronic liver disease and 3.4% had cirrhosis. Abnormal liver tests on admission were present on 45.2% (CI 42.7‚Äď47.7) of the cohort (n = 726). Overall, 15.1% (CI 13.4‚Äď16.9) of patients died (n = 244). Patients with abnormal liver tests on admission presented higher mortality 18.7% (CI 15.9‚Äď21.7), compared to those with normal liver biochemistries 12.2% (CI 10.1‚Äď14.6); P 30. Conclusions: The presence of abnormal liver tests on admission is independently associated with mortality and severe COVID-19 in hospitalized patients with COVID-19 infection and may be used as surrogate marker of inflammation.Fil: Mendizabal, Manuel. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Pi√Īero, Federico. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Cient√≠ficas y T√©cnicas. Oficina de Coordinaci√≥n Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones M√©dicas e Investigaciones Cl√≠nicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Anders, Margarita. Hospital Aleman; ArgentinaFil: Silveyra, Mar√≠a Dolores. Sanatorio Anchorena; ArgentinaFil: Torre, Aldo. Centro M√©dico ABC; M√©xicoFil: Montes, Pedro. Hospital Nacional Daniel A. Carri√≥n; Per√ļFil: Urz√ļa, Alvaro. Hospital Cl√≠nico de la Universidad de Chile; ChileFil: Pages, Josefina. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Toro, Luis G.. Hospitales de San Vicente Fundaci√≥n de Medell√≠n y Rionegro; ColombiaFil: D√≠az, Javier. Hospital Nacional Edgardo Rebagliati Martins; Per√ļFil: Gonzalez Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Cl√≠nicas General San Mart√≠n; ArgentinaFil: Miranda Zazueta, Godolfino. Instituto Nacional de Ciencias M√©dicas y Nutrici√≥n; M√©xicoFil: Peralta, Mirta. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Mu√Īiz"; ArgentinaFil: Guti√©rrez, Isabel. Centro M√©dico ABC; M√©xicoFil: Michelato, Douglas. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; BrasilFil: Venturelli, Maria Grazia. Hospital Nacional Guillermo Almenara Irigoyen; Per√ļFil: Var√≥n, Adriana. Fundaci√≥n Cardio-Infantil; ColombiaFil: Vera Pozo, Emilia. Hospital Regional Dr. Teodoro Maldonado Carbo; EcuadorFil: Tagle, Mart√≠n. Cl√≠nica Anglo-Americana; Per√ļFil: Garc√≠a, Mat√≠as. Centro de Educaci√≥n M√©dica e Investigaciones Cl√≠nicas "Norberto Quirno"; ArgentinaFil: Tassara, Alfredo. Hospital Aleman; ArgentinaFil: Brutti, Julia. Sanatorio Anchorena; ArgentinaFil: Ruiz Garc√≠a, Sandro. Hospital de V√≠ctor Lazarte Echegaray; Per√ļFil: Bustios, Carla. Cl√≠nica Delgado; Per√ļFil: Escajadillo, Nataly. Hospital Nacional Almanzor Aguinaga Asenjo; Per√ļFil: Macias, Yuridia. No especif√≠ca;Fil: Higuera de la Tijera, F√°tima. Hospital General de M√©xico ‚ÄúDr. Eduardo Liceaga"; M√©xicoFil: G√≥mez, Andr√©s J.. Hospital Universitario Fundaci√≥n Santa F√© de Bogot√°; ColombiaFil: Dominguez, Alejandra. Hospital Padre Hurtado; ChileFil: Castillo Barradas, Mauricio. Hospital de Especialidades del Centro M√©dico Nacional La Raza; M√©xicoFil: Contreras, Fernando. No especif√≠ca;Fil: Scarpin, Aldana. Centro de Educaci√≥n M√©dica e Investigaciones Cl√≠nicas "Norberto Quirno"; ArgentinaFil: Schinoni, Maria Isabel. Hospital Alianza; BrasilFil: Toledo, Claudio. Universidad Austral de Chile; ChileFil: Girala, Marcos. Universidad Nacional de Asunci√≥n; ParaguayFil: Mainardi, Victoria. Hospital Central De las Fuerzas Armadas; UruguayFil: Sanchez, Abel. Hospital Roosevelt; GuatemalaFil: Bessone, Fernando. Provincia de Santa Fe. Ministerio de Salud y Medio Ambiente - Rosario. Hospital Provincial del Centenario; ArgentinaFil: Rubinstein, Fernando Adrian. Instituto de Efectividad Cl√≠nica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Cient√≠ficas y T√©cnicas; ArgentinaFil: Silva, Marcelo Oscar. Universidad Austral. Hospital Universitario Austral; Argentin

    Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

    Get PDF
    Background: Approximately 450‚ÄČ000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2¬∑1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13¬∑0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63‚ÄČ093 individuals in the FHSC registry, 11‚ÄČ848 (18¬∑8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50¬∑2%) of 11‚ÄČ476 included individuals were female and 5720 (49¬∑8%) were male. Sex data were missing for 372 (3¬∑1%) of 11‚ÄČ848 individuals. Median age at registry entry was 9¬∑6 years (IQR 5¬∑8-13¬∑2). 10‚ÄČ099 (89¬∑9%) of 11‚ÄČ235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10¬∑1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5¬∑2%) of 11‚ÄČ848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92¬∑4%] of 10‚ÄČ202) than in children and adolescents from non-high-income countries (199 [48¬∑0%] of 415). 3414 (31¬∑6%) of 10‚ÄČ804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72¬∑4%) of 10‚ÄČ428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5¬∑00 mmol/L (IQR 4¬∑05-6¬∑08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

    Control estadístico para la calidad de proveedores

    No full text
    Este trabajo muestra la aplicaci√≥n de la metodolog√≠a de dise√Īo de experimentos en una empresa para identificar los niveles √≥ptimos de los factores que afectan la calidad de su producto, proceso y servicio para que se cumpla con las expectativas con el m√≠nimo n√ļmero de pruebas

    La coordinaci√≥n interinstitucional de pol√≠ticas p√ļblicas en ausencia de jerarqu√≠as : las pol√≠ticas de juventud en Sonora

    No full text
    Tesis Maestr√≠a en ciencias sociales El Colegio de Sonora 2003 Pol√≠ticas p√ļblica
    • ‚Ķ
    corecore